Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

Objectives Despite the publication of hundreds of trials on gout and hyperuricemia,
management of these conditions remains suboptimal. We aimed to assess the quality and …

ABSTRACT Introduction: Adverse drug reactions (ADRs) are a major health concern
worldwide. There are multiple causes of ADRs, some of which are preventable …

Response to a drug often differs widely among individual patients. This variability is
frequently observed not only with respect to effective responses but also with adverse drug …

Individuals differ substantially in their response to pharmacological treatment. Personalized
medicine aspires to embrace these inter-individual differences and customize therapy by …

Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR
are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent …

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS),
toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms …

The clinical implementation of pharmacogenetic biomarkers continues to grow as new
genetic variants associated with drug outcomes are discovered and validated. The number …

Immune‐mediated drug hypersensitivity reactions are an important source of iatrogenic
morbidity and mortality. Human leukocyte antigen (HLA)‐B* 57: 01, HLA‐B* 15: 02, HLA‐A …